Campbell & Co Investment Advisors LLC will renew its stake in Haemonetics (NYSE:HAE – Valuation Acquired) during the fourth quarter, according to the company’s latest disclosure filing with the Securities and Exchange Commission. Said he bought it. The fund purchased 14,347 shares worth approximately $1,128,000 in medical device suppliers.
Other hedge funds and institutional investors have also recently changed their stakes in the company. Romano Brothers AND Company bought his new position in Haemonetics during the fourth quarter worth $31,000. Eagle Bay Advisors LLC increased his position in Haemonetics by 23.6% in the fourth quarter. After Eagle Bay Advisors LLC acquired an additional 151 shares during the period, he now owns 792 shares of the medical device supplier worth $62,000. Altshuler Shaham Ltd purchased new shares in his Haemonetics worth approximately $59,000 during the third quarter. CoreCap Advisors LLC purchased new shares of his Haemonetics worth approximately $70,000 in the fourth quarter. Finally, Captrust Financial Advisors increased its stake in Haemonetics shares by 33.4% during the first quarter. Captrust Financial Advisors purchased an additional 585 shares last quarter and now owns 2,335 shares of the medical device supplier, valued at $148,000.
Wall Street analysts forecast growth
HAE has been the subject of several recent research reports. Citigroup lowered its price target on Haemonetics to $90.00 from $95.00 in a research note on Monday, April 3. JMP Securities raised its price target on Haemonetics from $105.00 to $115.00 in a research note on Friday, May 12. Barrington Research raised its price target on Haemonetics to $111.00 from $103.00 in its research report on Friday, May 12. Finally, StockNews.com downgraded Haemonetics stock from a “strong buy” rating to a “buy” rating in its research report on Monday, June 5th. Two research analysts have a Hold rating on the stock, while five have a Buy rating. Based on MarketBeat data, Haemonetics has an average rating of “Moderate Buy” and an average target price of $103.17.
Haemonetics trading down 0.2%
Haemonetics shares opened Friday at $88.14. Haemonetics hit a one-year low of $58.23 and a one-year high of $91.39. His 50-day moving average for this company is $84.43 and his 200-day moving average is $82.28. The stock has a market cap of $4.45 billion, a P/E ratio of 39.52 times, a price/earnings multiple of 2.48 times, and a beta of 0.43 times. The company has a debt to equity ratio of 0.92, a current ratio of 3.06 and a quick ratio of 2.03.
Haemonetics (NYSE:HAE – Rated) last reported earnings on Thursday, May 11. The medical device supplier reported earnings per share (EPS) of $0.77 for the quarter, beating consensus expectations of $0.68 by $0.09. Haemonetics had a net profit margin of 9.87% and a return on equity of 20.13%. The business had sales of $304.42 million in the quarter, compared with analyst expectations of $284.53 million. On average, sell-side analysts expect Haemonetics to post an EPS of $3.55 this year.
In other Haemonetics news, EVP Anila Lingamuneni sold 2,304 shares in the company in a transaction on Tuesday, May 30th. The shares were sold at an average price of $83.33 for a total transaction value of $191,992.32. Upon completion of the sale, the Executive Vice President will own directly 16,800 shares of the Company’s stock, valued at approximately $1,399,944. The sale was disclosed in her SEC filings, which are available at this link. Currently, 1.65% of the shares are owned by corporate insiders.
Haemonetics Company Profile
Haemonetics Corporation is a healthcare company providing an array of medical products and solutions in the United States and globally. The company offers automated plasma collection systems, donor management software, NexSys PCS and PCS2 plasmapheresis machines, related disposables and supporting software solutions including intravenous solutions, as well as integrations for plasma customers to manage their donors, operations and supply chain. We provide an information technology platform. ; NexLynk DMS Donor Management System, and Donor360.
This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments regarding this story to email@example.com.
Listen to this before you consider Haemonetics.
MarketBeat tracks Wall Street’s highest-rated, highest-performing research analysts and the stocks they recommend to clients every day. Marketbeat identified five stocks top analysts are secretly whispering to customers to buy now before the whole market goes viral, but Haemonetics wasn’t on that list.
Haemonetics currently has a “moderate buy” rating among analysts, although high-scoring analysts think these five stocks are better buys.
Click here for 5 brands